Depending on the content you would like to see, certain cookies must be activated. Some are essential while others are necessary to improve your virtual event experience.
These cookies are necessary to enable the full functionality of login, conferences and more. Therefore, these cookies cannot be deactivated.
We would like to present you various contents for which cookies are required. To agree, please choose the according checkbox.
Heinke von Seggern joined Roche in Basel in 2009. He moved into his current role as Head Sustainability Roche HQ Site Basel/Kaiseraugst in January 2020. Before that, he worked at Roche in various global functions with increasing responsibility in the areas of sustainability, compliance and risk management in procurement and in the supply chain. Before his time with Roche, he worked in various management positions in the areas of research & development, business assessment, purchasing and supply chain at Hoechst AG, Novartis and Syngenta. Heinke holds a Ph.D. in organic chemistry from the Albert-Ludwigs-University in Freiburg / Germany and a post-doctoral fellowship at the University of California in Santa Barbara, USA.
Margo is co-director of Business for Health Solutions, an innovative private sector approach to health systems strengthening in Africa, and a consultant with the Global Development Incubator. Margo has enjoyed a diverse career in corporate & development finance, training and CSR and is experienced working in large multinationals and the non-profit sector. Her health sector expertise was gained during 15 years with Novartis and with the Swiss Malaria Group. Margo has a Diploma in CSR from the University of Geneva, is a Chartered Accountant and is a board member of the Swiss non-profit Terre des Hommes Schweiz.
Jean-David Malo studied in the Institut National Supérieur des Sciences Economiques et Commerciales (Paris) and the University of California (Berkeley). He started his career as Head of internal control management in the Comité Professionnel de la Distribution de Carburants in France before joining ARMINES, a body managing contractual research and innovation for French engineering schools (Ecoles des MInes, Ecole Polytechnique, ENSTA, …), where he created, developed and managed the European Affairs Directorate.
He joined the European Commission in January 2001. In the Directorate General for Research, he participated actively to a number of developments on the design of funding instruments, rules for participation, funding schemes, etc, both for FP6 and FP7.
From 2003 to 2006, he was the assistant of Director Robert-Jan SMITS. After heading the unit in charge of the regional aspects of FP7, ie. the "Regions of Knowledge" and "Research Potential" programmes, from 2006 to 2010, he was managing from 2011 to 2013 a newly created unit in DG Research and Innovation, the main objective of which was to contribute to increase private finance and close market gaps in investing in research and innovation by expanding the scope and scale of existing EU innovative financial instruments (like the Risk-Sharing Finance Facility) and by developing new ones in the fields of debt (including guarantees) and equity financing, notably in the context of Horizon 2020 ("InnovFin"). The EU state aid framework, tax incentive schemes and philanthropic funding were also areas covered by the work of the unit. From 2014, this unit was also covering the SMEs dimension of Horizon 2020, including in particular EUROSTARS II and the design and coordination of the SME Instrument and the Fast Track to Innovation pilot.
In February 2017 he was appointed Director of the Directorate in charge of "Open Innovation and Open Science". The European Innovation Council (EIC), the VentureEU Initiative, the RDI dimension under the European Fund for Strategic investments, the European Open Science Cloud, the long-term sustainable investments for Research Infrastructures, the monitoring of the ERA Roadmaps, etc… are among the various files he is in charge of or contributing to.
In June 2019 he was appointed Director of the European Innovation Council Task Force. The EIC TF main missions are (1) ensure the efficient implementation of the Enhanced EIC pilot under Horizon 2020 and prepare the conditions for a scale up under Horizon Europe; (2) to provide overall policy support and strengthen/develop the innovation ecosystems within which innovation can flourish; and (3) to foster financial conditions required to boost the competitiveness and growth of R&I-driven enterprises, in particular deep-tech start-ups and SMEs (in the context of EFSI/InnovFin and then InvestEU). He is also a member of the EFSI Steering Committee and an alternate member of the EIF Board of Directors; as well as High Level Representative of the Commission in EUREKA.
Johannes Tervo - Head of Partnerships at Slush
Johannes believes in entrepreneurship as a means to solve some of the biggest problems in the world.
Currently, he's working at Slush – the world’s leading startup event & ecosystem organization. He's responsible for building partnerships between Slush, the startup ecosystem, and industry-leading companies globally.
André Hoffmann is Vice Chairman of Roche Holding Ltd. Alongside his non-executive roles in the family business, he has a distinguished cursus in nature conservation and sustainability. He is the President of Fondation MAVA and of Fondation Tour du Valat in the Camargue. He has joined the Board of SystemIQ to help positively disrupt critical economic systems; the Board of Trustees of the World Economic Forum and the Center for the Fourth Industrial Revolution in San Francisco. He is Chairman of the Advisory Board of the Hoffmann Global Institute in Business and Society (HGIBS) at INSEAD.
Since 2016 at Roche started in Patient Partnership in the Swiss Affiliate then moved to Global in Fall 2018. Current role "Senior Patient Partnership Director" in the Patient Partnership Team (PDMA).
Background: PhD in Molecular Tumour Biology, UCL London (London Research Institute), Master in Cell Biology (ETH, Switzerland)
Strong interest in Innovation and start-up support
Dr Carlo Messina is Sr Medical Director for Oncology and Infectious Disease in Medical and Scientific Affairs for Diagnostics Global Business Development, Basel, Carlo joined Roche in 2015. Prior to Roche Carlo worked as a Clinical Research Physician at European Organization and Treatment of Cancer (EORTC) Headquarters in Brussels, writing protocols and managing trials mainly with Gastro-Intestinal Cancer Group and Breast Cancer Group. He has also worked as Medical Oncologist treating patients with solid tumors and actively participating in Genito-Urinary Cancer clinical trials as an investigator at the San Camillo and Forlanini Hospitals in Rome. Carlo is a Board Certified Medical Oncologist (Italy), holds a Medical Degree from the University of Catania (Italy), a post-graduate Degree in Biochemistry from University College London (UK) and a specialization in Medical Oncology from the University of Rome “La Sapienza” (Italy).
Vivienne Parry is a UK science writer and broadcaster. She also has many other roles including board member of UK Research & Innovation, the body responsible for the strategic spend of the UK’s £7 billion annual research and innovation budget, and part time head of engagement at Genomics England. She is best known in the UK for being a presenter on the BBC’s iconic innovation show, Tomorrow’s World. She works many entrepreneurs and start ups communicate their science more effectively.
Dr. Alexandra Vallon-Eberhard
Senior Director Global Diagnostics BD
Dr. Alexandra Vallon-Eberhard has over 15 years of extensive international business
development, investment, innovation and managerial experience. She is focusing her work
on personalized patient care and digital healthcare solutions, currently serving as Senior
Director Global Business Development – Diagnostics Biomarkers and Digital Healthcare
Solutions at Roche.
Alexandra successfully co-built the 2019 Frost & Sullivan awarded next-gen data platform
(Sequoia-backed) and supported over 40 of the fortune 500 companies in their
inorganic/venture growth strategy in the era of digital transformation. Over the past 10 years,
Alexandra has accompanied Israeli and Swiss start-ups in their financial, strategic and
Since 2020, she is a proud board member of the Weizmann Young European Network,
expert member of the digital health hub @Lausanne Biopole and volunteer of the Healthcare
Alexandra earned her PhD in Immunology/Virology at bioMerieux (France), her post-
doctorate at the Weizmann Institute of Science (Israel) and received six academic awards.
Alexandra also earned an International MBA from Bar Ilan University (Israel).
Being diagnosed with inflammatory bowel disease in 2008 completely changed my life. It has shaped the person I am - from how I live day-to-day and the perspective I have on the world, to the work I do and the people I surround myself with. Most importantly, it’s given me a passion to improve care and access to information for patients.
Discovering more about my disease and my body has helped me to gain remission, but it’s also meant I’ve had to make a lot of changes and sacrifices to get there. Would I change any of it? No. Not for a second. I’m happier and healthier now than I’ve ever been.
I love sharing my learning with other patients and healthcare professionals through my advocacy work and speaking at events. But, I’m also finding solutions to some of the big healthcare problems to empower patients and place them at the heart of it all. That’s why I’m passionate about the mentoring, consultancy and entrepreneur parts of the work I do. I plant seeds of change to help healthcare grow into what patients really need.
Theresa leads a new group called Customer Interface Innovation at Pharma International in
Basel which was formed to reimagine (and disrupt) customer interface and engagement
with the goal of creating exceptional and meaningful customer experiences.
Prior to this, Theresa was General Manager at Roche Philippines for a little over four years.
In that time, she led and inspired several local and global teams to deliver more value for
our customers through operating model innovation including disruptive ways of working.
One her proudest moments is the signing into law of the Philippine Cancer Bill in early 2019.
During her long international career, Theresa held various leadership roles as LifeCycle
Leader for Taselisib and Perjeta at Genentech and prior to that a variety of roles with
increasing responsibility at Roche/Genentech. Theresa started her career in pharmaceuticals
Connie is from Singapore, and is a Master of Science graduate of Imperial College London, UK (Business and Environment). Her work experience and passion to date revolved around Human Rights and Sustainability topics, particularly in large corporate supply chains and she has a large network engaged in sustainability topics globally. Currently, she is one of the Co-Founders at Impact Hub Basel and focuses her energy on building the team, strategy and creating meaningful content. Connie is a visionary who can dream big out of simple ideas. Her empathy and instinctive ability to understand others enables her to connect, adapt and relate. Connie truly believes that the power of curated collaboration can create a bigger impact and a better world.
Katell Le Goulven joined INSEAD in April 2018 as the founding Executive Director of the Hoffmann Global Institute for Business and Society. Previously with UNICEF, she founded a Policy Planning unit to analyze global trends and emerging issues and inform UNICEF’s strategic positioning, and led UNICEF’s corporate engagement with International Financial Institutions.
She has held senior positions with high-level commissions that defined the policy implications of the data revolution, climate change, and global public goods for the development agenda. She has over 20 years of professional experience at the interface of research and decision-making designing policies and strategies, and advising senior executives in international organizations and governments. She holds a PhD in agricultural economics, a Msc. in tropical agronomy, and an engineering degree. She lives in Fontainebleau with her husband and three children.
Lauren enjoys consulting in the healthcare/pharma industry regarding telemedicine, social media, adherence and empowerment of the patient. She melds her life experience thriving despite cystic fibrosis with her professional experience in the rigorous product design consultancy world to bring a unique perspective to care management. Additionally, she shares her wealth of health knowledge as a wellness advocate leading a team of wellness coaches internationally. As Chief Operating Officer of CFTechnology she is leading the way for the cystic fibrosis community to access, consent and be compensated to share their data. Lauren enjoys tennis, golf, dancing, fundraising and has personally participated in multiple clinical trials.
Alice is the Director of GDI’s Social Enterprise Accelerator and author of the recently published "What's Your End-Game Article" for nonprofits to define not only the impact they seek, but the ultimate sector change each aims to create. The GDI Social Enterprise Accelerator is an innovative, portfolio based approach to grow the impact and reach of non-profits during a 2 year acceleration process. The Accelerator brings together a task force of world-class experts from fundraising and financial management to communications and strategy that work hand in hand with non-profit teams across regions and functions. Together, we implement programs, develop capabilities, re-prioritize efforts in real time and realize greater impact. Alice is also a serial entrepreneur in the non-profit and for-profit sectors having co-founded The Muskoka Foundation and the “Do Good As You Go” movement and Infinite Monkeys, a drag and drop platform that enables anyone to build their own mobile app without coding. Prior these ventures, Alice worked with The Bridgespan Group in San Francisco on high school education reform with the Gates Foundation, started Bain & Co’s Pro-Bono practice in Asia specializing in non-profit collaboration practices and government non-profit oversight, worked with the World Bank, Bain & Co in Singapore and Bangkok and started the MNC fixed income derivatives desk for BTM in SE Asia. Alice graduated from Stanford Japan Center, Columbia College and Harvard Business School.
Joanne M. Hackett leads the Healthcare Practice at IZY Capital where she works with, incubates and grows the next generation of world leading innovators.
Professor Hackett is a clinical academic, entrepreneur, investor, and a strategic, creative visionair with global experience spanning successful start-ups to Fortune 500 companies. Aside from her curious passion for life and positivity, Joanne is known for building innovation, driving personalised medicine and leading through fast paced, complex changing ecosystems and integrations. Joanne's goal is to contribute in bringing the world novel, cost effective and simple health care solutions, and she is particularly keen on building the case for prevention, open science and citizen genomics. She has extensive global experience across academic, business and clinical institutions, and enjoys sharing her experiences with the Boards she sits on as well as companies she provides strategic advice to.
Joanne has been publicly recognised for her relentless pursuit of revolutionising healthcare and has recently been named one of the top six Influential Leaders in Healthcare by CIO Look, the Accenture Life Science Leader of the year 2019, Freshfields Top 100 Most Influential Women 2019, One HealthTech 2018 Top 70 Women in the NHS, Pharmaceutical Market Europe’s 2018 30 women leaders in UK healthcare and BioBeat 2017 Top 50 Women in Biotech Award. Joanne believes in human courage and perseverance against the odds, and demonstrates that positive change, whether in a company or in one’s personal life, can be carved out from even the greatest of trials. As a believer of ‘health = wealth’, Joanne is an internationally known yoga instructor.
Mark Lee, MD, PhD
SVP PD Head PHC 2.0
Mark Lee is a medical oncologist and the Global Head for Personalized Healthcare, Product Development at Genentech/Roche.
Prior to joining Genentech, Mark was a member of the founding leadership team and Head of Clinical Development and Medical Affairs at GRAIL, where he built one of the largest clinical research programs in genomic medicine aimed at early cancer detection. Mark’s previous roles include Lead for Oncology Clinical Sciences at Google[x] Life Sciences, Chief Medical Officer at Boreal Genomics, and Vice President of Oncology Development at Genomic Health, where he led the successful development and validation of the Oncotype DX Colon and Prostate Cancer Assays. His prior work also includes design and conduct of clinical trials for tissue-based and molecular imaging biomarker discovery at Genentech.
Mark holds a PhD in Biological Chemistry and Molecular Pharmacology from Harvard, and a MD from Stanford University, where he completed his internal medicine training and medical oncology fellowship.
Aviad Tamir is the Head of Life Sciences & Healthcare at Invest in Israel, helping multinationals establish their operations in Israel.
His professional experience spans across Israel and abroad working with Pharmaceutical & Healthcare industries, specializing in International Business Development & Strategic Partnerships within the private and public sectors.
Previously, Aviad worked at the Ministry of Defense, Mission to the U.S. managing procurement projects for the IDF, and the Office of the Prime Minister as an Advisor to the Director General of the Ministry for Senior Citizens.
Arianne is Circular Business Design Lead at IDEO in London. Passionate about tackling systemic, social and environmental challenges, she co-leads the Circular Economy portfolio for IDEO's CoLab, collaborating with the textiles industry, startups and academia to explore opportunities to design out waste, and create value through design.
She's an industrial & systems engineer and MBA with cross-industry experience from logistics to pharmaceuticals in a variety of roles ranging from managing warehouse operations, to marketing in diabetes, to leading a cultural transformation towards customer centricity. Her diverse background and professional experiences have allowed her to develop a systems view and an understanding of the organisational challenges of change initiatives, while always keeping human needs at the centre.
Anton joined mySugr early in 2013, leaving his strategic consulting career in order to start a business in the diabetes industry out of his own frustration of living with diabetes. A couple of years later, mySugr is the #1 diabetes management app, changing the lives of millions of people with diabetes around the world. Anton and the team closed several rounds of financing, deals with big pharma and medical device companies, ultimately joining the Roche family in summer 2017. Today Anton is the CEO of mySugr, leading a team of 170+ employees and is based in Vienna, Austria.
Miro Venturi, Ph.D., M.Sc., joined Foundation Medicine as SVP, Head of Biopharma in December 2019. Dr. Venturi brings over 15 years of experience in pharmaceutical R&D and diagnostics, building business strategies for drug discovery and diagnostics product development across therapeutic areas including oncology, infectious diseases, immunology, and rare diseases. Dr. Venturi is passionate about ensuring better access to precision medicine through the development of companion diagnostics, data models, and strong partnerships in the development of new therapeutic options.
Dr. Venturi joined Foundation Medicine from Roche, where he served as the global head of diagnostics biomarkers and personalized healthcare. He established strategies to further Roche Diagnostics’ work in biomarker development and implemented projects to address areas of unmet medical need and other business opportunities. Dr. Venturi also led the personalized healthcare strategy between Roche Diagnostics and other pharmaceutical divisions within the company.
Prior to joining Roche, Dr. Venturi was the division head of biomarker development at Novartis Pharmaceuticals, where he was responsible for overseeing biomarker and bio-analytical assays development to support research and development efforts. Before that, he served as the head of analytical biology at Nerviano Medical Sciences.
Dr. Venturi holds a Ph.D. in biochemistry from the Max-Planck Institute of Biophysics in Germany and a M.Sc. in biological sciences from the University of Bologna, Italy. He completed his post-doctoral fellowship at the National Institutes of Health.
Michael Haessler has been working for Roche since 2016. In his current role as Senior Sustainability Manager, Michael is responsible for driving sustainability awareness and culture at the Site Basel/Kaiseraugst, the coordination of value-adding sustainability projects and contribution to the integration of sustainability into business strategies. Before this, Michael was leading the Roche Global Scientific Communications Team for Personalized Healthcare. Before joining Roche, Michael was heading the Scientific Communications Team at SAN GmbH (Science Agency and Network) in Switzerland. Michael holds a Ph.D. in Neuroscience from the Swiss Federal Institute of Technology Lausanne (EPFL) and is an ISMPP Certified Medical Publication Professional.
Steven (Steve) Bourke is an inspired and genuine advocate for people who are patients. He is passionate about creating opportunities to allow individuals and communities to take ownership of their disease through collaboration and education. His background blends expertise in health communication, biomedical research, and exercise science; the ultimate goal is to help develop relevant and innovative solutions in healthcare through long-term valued based partnerships. As a member of EUPATI Switzerland (European Patients Academy) and a founding Board Member of RheumaCura Foundation (Foundation for Patient-Centric Arthritis Research), he is actively driving forward engagement for people who are patients.
Benoît Legrand Chief Innovation Officer, ING CEO ING Ventures
Benoît Legrand (51) began his career as an investment banker at Bank Bruxelles Lambert in 1994, before it became ING Belgium. He rejoined the Group a few years later, after founding his own start-up company in retail distribution.
Benoît has an extensive international experience within the ING Group having worked in Investment Banking, Retail and Private Banking covering diverse areas such as Marketing, Sales, Branch Distribution and Product Management in Belgium, Singapore, Poland, the Netherlands and France.
In 2007 he was appointed to the Executive Board of ING Nederland where he lead the total make-over of Private Banking and Securities and took an active part in the merger of Postbank and ING Bank.
He was appointed CEO of ING Direct France in 2010 and Country CEO ING France in 2013, after merging all retail, commercial banking and real estate activities in France into one single integrated entity.
In 2015, Benoît has been appointed President of ING Bank France and Global Head of FinTech and subsequently CEO of ING Ventures, ING’s EUR 300m Corporate Venture Capital arm, being instrumental in ING’s innovation leadership.
Since January 2018, Benoît is ING’s Chief Innovation Officer.
Benoît graduated in Economics from Catholic University of Leuven and in International Relations from the London School of Economics.
After completing a degree in Pharmacology, Ravi gained employment in non-health and health
related sectors, undertaking Sales, Marketing, Market Access, Business Development and Health
Economics roles. Prior to re-joining Roche Diagnostics Ravi undertook projects for the UK
Department of Health and also for the UK Department for International Trade. A major area of focus
within these roles was to assist HealthTech innovators (SMEs and Large organisations) gain access to
the most appropriate experts in UK Universities and the NHS. He has also been part of various
working groups within the National Institute of Health and Clinical Excellence (NICE), National
Institute for Health Research (NIHR), the British In-Vitro Diagnostics Association (BIVDA) and
Association of British Healthtech Industries (ABHI).
Ravi’s role as Head of Business Development focuses on assessing innovative technologies and
companies, which could fit the Roche Diagnostics portfolio or be potential partners for the UK
affiliate to work with across patient care pathways. Areas of particular focus are Cardiac Disease,
Oncology, Women’s Health, Alzheimer’s and Infectious Diseases, with Digital Health as a cross
cutting theme of interest. The role also allows Ravi to work closely with the Roche Global Business
Development team to bring any potential technologies to the Roche global organisation to assess.
Ravi is currently Vice Chair of the ABHI Digital Health Group, where he works with likeminded
industry colleagues to assess the healthcare landscape for the evaluation and uptake of digital
health technologies into the healthcare system.
Outside of work Ravi is a keen Field Hockey Player and Coach, focusing on developing young talented
individuals who want to progress in their chosen sport and provide guidance where needed.